KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Common Equity (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Common Equity data on record, last reported at $85.1 million in Q3 2025.

  • For Q3 2025, Common Equity rose 74.06% year-over-year to $85.1 million; the TTM value through Sep 2025 reached $85.1 million, up 74.06%, while the annual FY2024 figure was $60.7 million, 53.63% down from the prior year.
  • Common Equity reached $85.1 million in Q3 2025 per NKTR's latest filing, up from -$24.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $994.5 million in Q1 2021 and bottomed at -$24.2 million in Q2 2025.
  • Average Common Equity over 5 years is $333.9 million, with a median of $197.0 million recorded in 2023.
  • The widest YoY moves for Common Equity: up 74.06% in 2025, down 130.38% in 2025.
  • A 5-year view of Common Equity shows it stood at $679.5 million in 2021, then tumbled by 46.04% to $366.6 million in 2022, then plummeted by 64.27% to $131.0 million in 2023, then plummeted by 53.63% to $60.7 million in 2024, then soared by 40.09% to $85.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $85.1 million in Q3 2025, -$24.2 million in Q2 2025, and $13.7 million in Q1 2025.